

## Angus HSCP Prescribing Management Plan: Update of Active Interventions 2019/20

Initiative	Rationale	Actions	Lead	Status (RAG)
<b><i>Being dynamic to change</i></b>				
<b>Practice review report 19/20</b>	Provision of key information to practices to enable discussion and identify areas to address	Plans to be issued to practices by 1 May 2019	<b>SJ</b>	
		Practice priorities for action in 2019/20 to be submitted to HSCP by 1 <sup>st</sup> June 2019	<b>MLR</b>	
		Audits and claims for all actions completed to be submitted by 31 <sup>st</sup> Dec 2019	<b>RG</b>	
		Audits to be used to inform 2020/21 priorities	<b>SJ</b>	
<b>Maintaining momentum</b>	To maintain profile and momentum around prescribing position in relation to prescribing	Prescribing as a standing item with a written report at each Clinical Partnership Group meeting.	<b>SJ/MLR</b>	
		Continued review of top 70 GIC every quarter to monitor and adapt ongoing plans.	<b>SJ</b>	
		Annual PLT programme on prescribing topics to support high quality prescribing and realistic medicine	<b>RG/SJ</b>	
		Increase links with non-medical prescribers to maintain best value prescribing choices across all prescribers	<b>KF</b>	
<b>Monitoring of formulary compliance</b>	Formulary choices are based upon cost effectiveness and clinical best practice	Ongoing review of high cost non-Formulary choices, passed to practices to review	<b>JM/RP/SJ</b>	
<b>Establishment of Prescribing of Non-Medicines Advisory Group</b>	To ensure cost effective use of prescribed non-medicines	A regional group co-chaired by Angus' Prescribing Clinical Lead, will identify further areas of improvement for Non-medicines prescribing within 2018/19	<b>SJ</b>	
		Adoption of novel pathways from PONMAG reviews. Pilots completed for stoma, ONS baby milk. Pending catheter/dressings	<b>SJ</b>	
<b>Technical prescribing efficiencies</b>	Ensure opportunities are identified to maximise technical efficiencies/switches	Regionally coordinated and locally implemented switches are expedited where clinically safe and approved by local prescribing leads.	<b>SJ/MLR/HS /MB</b>	

<b>Horizon scanning</b>	Ensure early identification in event of pricing changes and/or local deterioration in prescribing position	Clinical lead and Prescribing Support Unit monitoring	<b>SJ/SB/HS</b>	
<b><i>Making best use of resources</i></b>				
<b>Pharmacotherapy service development</b>	A requirement of the 2018 GMS contract we will create capacity and the potential to support improved shared learning in prescribing and management of prescribing processes across Angus.	Implementation of the pharmacotherapy actions as outlined in the Primary Care Improvement Plan.	<b>MLR/RG</b>	
<b>Improved prescribing of psychotropics through improved mental health pathways</b>	Key priority for 2018/19 regionally recognising impact of mental health prescribing on variation and spend- with risk in some cases of harm	Angus will support the optimised use of psychotropic medications and making best use of non-drug options. Integrate psychiatric services to clusters with improved signposting to non-drug options.	<b>BT/AC/SJ</b>	
<b>Diabetes Pathway Reviews</b>	Key regional priority for 2018/19 recognising variation in spend and potential harm	Angus will support the development, testing and implementation of new regional pathways with an increased emphasis on supporting lifestyle changes and a more personalised approach to diabetes management. (including CCP testing). Cluster based delivery of all diabetes care.	<b>CS/AC/NG/MJ</b>	
<b>Improved access to non- drug options</b>	To reduce harms of medications and improve access to non-drug options across Angus	In line with nGMS contract to continue implementation of level 1 mental health support, physiotherapy and social prescribing within practices	<b>BT/RG/AC</b>	
<b>Supply of non-medicines to care homes</b>	To improve cost effective supply chain	Increased support to care homes/nursing homes to source all non-medicines via PECOS where possible	<b>DD</b>	
<b><i>Quality Improvement of Practice Prescribing</i></b>				
<b>Medicines of low clinical value</b>	Support cost effective and efficient prescribing	Angus will support the planning process regionally and ensure implementation of recommendations locally as and when identified. Completed: sun cream, tooth paste, omega 3.	<b>SJ</b>	
<b>P-DQIP</b>	Improved use of P-DQIP will can improve the safety of prescribing	Ongoing roll-out of P-DQIP to practices. Integration of this tool within Pharmacist polypharmacy reviews. Initial piloting with 2 triggers. Reviewing into 2020 likely broadening adoption.	<b>MLR/SJ</b>	

<b>Supporting Effective Communications</b>				
<b>Improve both internal and external communication of prescribing changes</b>	To ensure accurate and consistent communication re current status to all prescribers and public members in Angus	Ongoing updates of ScriptSwitch to reflect current prescribing plans	<b>SJ</b>	
		Primary Care Prescriber bulletin developed monthly by Prescribing Lead and circulated to all prescribers	<b>SJ</b>	
		Monthly update to CPG on prescribing status	<b>MLR/SJ</b>	
		Technical switches discussed with practice lead prior to initiation	<b>JM/MLR</b>	
		Series of public communications plan which are complimentary to NHS Tayside wide communication plans. Indication for each medicine.	<b>AC</b>	

<b>GP Prescribing Initiatives</b>			
<b>National Therapeutic Indicators</b>	Practice targeting prescribing in line with NTI's	Practices engaged with use of NTI's to inform future prescribing review at practice level.	
<b>Polypharmacy</b>	Harm associated with polypharmacy is well evidenced.	Practices engaged with pharmacist supported and GP led Level 3 polypharmacy reviews for high risk community patients. Care homes polypharmacy levels reported in practice reviews 2019/20. Cluster driven prescribing quality improvement and reducing harmful prescribing driven by indicators within PDQIP for reviews by 2020.	
<b>Gabapentinoid/opiate review</b>	To improve safe prescribing.	Review of patients on >120mg opiate and/or Gabapentinoid	
<b>High cost psychotropics</b>	High spend, not always maximised non-drug options.	Review of high cost psychotropic prescribing. Where not recently reviewed consider whether still indicated, on formulary and if needing mental health support. Non-drug options maximised	

<b>Pharmacy team-led Initiatives</b>			
<b>High value, non-formulary prescribing monitoring</b>	Identify scale and governance processes related to this area of prescribing	All high value-non-formulary prescribing reviewed by practice pharmacy teams on searches done by JM/SJ. Where agreed assurance will be sought to affirm the ongoing prescribing.	
<b>Blood glucose testing in those on metformin/no anti-glycaemic except within DVLA guidance</b>	To only prescribe blood glucose monitoring where evidence supports use or legislation mandates	To review all patients on blood glucose monitoring sundries to ensure prescribing is indicated – pending release Jan 2020.	
<b>Top 70 GIC non-standard drug form review</b>	To ensure all forms of drugs prescribed in top 50 GIC are most cost effective	JM to extract any patients prescribed a non-cost- effective drug form of medicine appearing in Top 70 GIC to ensure this was intended. RP to support.	
<b>ScriptSwitch</b>	To review all high value declines	JM review high value declines to ensure consideration being given to the more cost- effective form. RP to supports.	
<b>Bisphosphonate</b>	Optimal use of medication	Assure use is within national guidelines including treatment duration, indication and reviewing of QFracture risk (shared with GP management)	
<b>NHS Tayside specialist service delivered initiatives</b>			
<b>Wound and catheter care</b>	Potential reduction in costs and wastage associated with moving from prescribing wound/catheter care to accessing via stock order	Service manager in Angus tasked with scoping, implementing and maximising roll out of regional programme in Angus.	
		PONMAG review to improve formulary prescribing rates of wound care and catheter products across NHS Tayside. Pending start at 2020.	
<b>Stoma Accessories</b>	Supported review of all patients to ensure management in line with revised formulary	Test process in one Angus practice	
		Complete Angus roll out	
		Extend to include stoma bags in 2019/20	
<b>Specialist baby milk</b>	Increased prescribing possibly leading to over- diagnosis	PONMAG review began Sept 18. Piloting of new pathway and milks has begun in Angus.	
<b>Diabetes consumables</b>	Improved use of diabetes consumables in line with NHST formulary	PONMAG review began November 18. Pending practice levels review Jan 2020.	

### **Lead abbreviations**

AC – Dr Alison Clement, Clinical Director Angus HSCP

SJ – Dr Scott Jamieson, Prescribing Lead Angus HSCP

MLR -Michelle Logan-Rena, Pharmacy Lead Angus

BT- Bill Troup, Head of Service, Mental Health RG – Primary Care Manager, Angus HSCP

HS – Hazel Steele, Lead Pharmacist, Prescribing Support

KF – Karen Fletcher, Lead Nurse, Angus HSCP

JM – Jenna Murray, Prescribing Support Pharmacy Technician BM

– Brian McGregor, Pharmacy Data Analyst, PSU NHS Tayside

CS – Dr Chris Schofield, Consultant Endocrinologist

MB – Mark Batey, Prescribing Support Technician, NHS Tayside

SB – Sandy Berry, Chief Finance Officer

NG – Dr Nico Grunenberg, GP Ravenswood

MJ – Dr Marc Jacobs, GP Edzell

RP – Ray pert – Porject Support Officer